search for
confirm
cancel

News Center

Innovation, accumulated accumulation, patents, mastering the future-Borui Medicine won the China Patent Award

  • Categories:NEW
  • Author:
  • Origin:
  • Time of issue:2017-11-14 14:45
  • Views:0

Innovation, accumulated accumulation, patents, mastering the future-Borui Medicine won the China Patent Award

(Summary description)Recently, the 19th China Patent Awards hosted by the State Intellectual Property Office of China announced that Borui Medicine's "Synthesis Method of Antiviral Nucleoside Analogs" stood out from the national excellent candidates and won the "China Patent Excellence Award" ( (Patent No .: ZL200610088464.8), which is the highest government award set by the country for inventions and creations, and represents China's highest honor for scientific and technological innovation and intellectual property.

  • Categories:NEW
  • Author:
  • Origin:
  • Time of issue:2017-11-14 14:45
  • Views:0
Information
1

Recently, the 19th China Patent Awards hosted by the State Intellectual Property Office of China announced that Borui Medicine's "Synthesis Method of Antiviral Nucleoside Analogs" stood out from the national excellent candidates and won the "China Patent Excellence Award" ( (Patent No .: ZL200610088464.8), which is the highest government award set by the country for inventions and creations, and represents China's highest honor for scientific and technological innovation and intellectual property.

The Borui participating patent disclosed a new production process of Entecavir. This patent fills a domestic technological gap, breaks through the patent barriers of foreign pharmaceutical giants, realizes import substitution in advance, significantly reduces the price of drugs, and restructures the domestic hepatitis B drug market structure; today, Entecavir has become the No. 1 oral medicine market in China. The three major varieties have annual sales of nearly 10 billion yuan, and more than 2.5 million patients benefit from it, which has greatly changed the status of China's "hepatitis B country".

The market share of Entecavir produced by Borui Medicine and its patent licensees and partners is as high as 80%, which has realized import substitution and also promoted the transformation and upgrading of upstream and downstream enterprises. With its patented technology, Borui Biotech supports domestic enterprises to produce entecavir drugs, drives related pharmaceutical companies to upgrade and transform, and promotes the development and growth of the pharmaceutical industry. Entecavir's market has all relied on imports from before, and now the domestic market share exceeds 80% . Borui is actively expanding more international markets for the benefit of hepatitis B patients worldwide.

Intellectual property is one of the core development strategies of Borui Medicine . Each year, a large amount of funds are invested in drug development, and the number and quality of patents formed are continuously improved, which strongly supports the company's expansion in the international market. In recent years, Borui Pharmaceutical 's investment in the field of intellectual property has gradually entered the harvest period, and has successively won "Suzhou Industrial Park High-Value Patents", "Suzhou Enterprise Intellectual Property Ascent Action Plan", "Jiangsu Intellectual Property Strategy Promotion Enterprise" "China Patent Excellence Award" and other honors are currently being applied for national intellectual property superior enterprises. With the in-depth implementation of the intellectual property strategy, Borui Medicine has more innovation momentumWill continue to contribute to the development of medicine and health.

About the China Patent Award The

"China Patent Award" was established by the State Intellectual Property Office in 1989 and has been selected for nineteen sessions. The evaluation criteria not only emphasize the project's patented technology level and innovation height, but also propose extreme protection and management status High requirements, with special emphasis on its use in the market transformation process, and the social and economic benefits of patents. This award is the only government department's highest award for inventions and inventions granted patent rights in China. It is recognized by the United Nations World Intellectual Property Organization (WIPO) and has international influence.

Back to top ▲

Borui Medicine

address:

Building C25-28, 218 Xinghu Road, Suzhou Industrial Park, Jiangsu Province, China

Borui Medicine

phone:

0512-62620988

 

Borui Medicine

Fax:
0512-62551799

Copyright: Brilliant Biomedical (Suzhou) Co., Ltd. Website: CE Dongli · Suzhou Su ICP No. 18,000,014           

Copyright: Borui Biomedical (Suzhou) Co., Ltd. 

Powered by www.300.cn 

苏ICP备18000014号